Table 2.
Patient demographics and baseline disease characteristics (Phase 3 trial)1
| Placebo | Setipiprant 1000 mg o.d. | Cetirizine 10 mg o.d. | |
|---|---|---|---|
| Patients, n | 210 | 210 | 210 |
| Age in years, mean (SD) | 37.5 (13.9) | 38.2 (15.1) | 40.7 (14.2) |
| Sex, (male: female) | 40%: 60% | 36%: 64% | 39%: 61% |
| Ethnicity, n (%): | |||
| Caucasian | 107 (51) | 102 (49) | 98 (47) |
| Black | 12 (6) | 13 (6) | 20 (10) |
| Hispanic | 90 (43) | 92 (44) | 89 (42) |
| Other | 1 (<1) | 3 (<2) | 3 (<2) |
| AR duration in years, mean (SD) | 17.4 (11.9) | 18.6 (11.5) | 18.9 (11.5) |
| Baseline DNSS, mean (SD)a | 2.16 (0.43) | 2.17 (0.41) | 2.22 (0.42) |
All-randomised set
AR allergic rhinitis, DNSS daytime nasal symptom score, SD standard deviation
aITT (intent-to-treat) set